215 related articles for article (PubMed ID: 17644731)
1. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.
Yang J; Zhang X; Wang J; Qian J; Zhang L; Wang M; Kwak LW; Yi Q
Blood; 2007 Oct; 110(8):3028-35. PubMed ID: 17644731
[TBL] [Abstract][Full Text] [Related]
2. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.
Cao Y; Lan Y; Qian J; Zheng Y; Hong S; Li H; Wang M; Kwak LW; Lin D; Yang J; Yi Q
Br J Haematol; 2011 Jul; 154(1):111-21. PubMed ID: 21554263
[TBL] [Abstract][Full Text] [Related]
3. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily.
Remacle-Bonnet M; Garrouste F; Baillat G; Andre F; Marvaldi J; Pommier G
Am J Pathol; 2005 Sep; 167(3):761-73. PubMed ID: 16127155
[TBL] [Abstract][Full Text] [Related]
4. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].
Abroun S; Ishikawa H; Tsuyama N; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Kawano MM
Blood; 2004 Mar; 103(6):2291-8. PubMed ID: 14592826
[TBL] [Abstract][Full Text] [Related]
5. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
6. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
Yang J; Qian J; Wezeman M; Wang S; Lin P; Wang M; Yaccoby S; Kwak LW; Barlogie B; Yi Q
Cancer Cell; 2006 Oct; 10(4):295-307. PubMed ID: 17045207
[TBL] [Abstract][Full Text] [Related]
7. Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.
Yang J; Yi Q
Cancer; 2010 Apr; 116(7):1638-45. PubMed ID: 20143445
[TBL] [Abstract][Full Text] [Related]
8. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
9. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
Tu Y; Gardner A; Lichtenstein A
Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
[TBL] [Abstract][Full Text] [Related]
10. Different associations of CD45 isoforms with STAT3, PKC and ERK regulate IL-6-induced proliferation in myeloma.
Zheng X; Li AS; Zheng H; Zhao D; Guan D; Zou H
PLoS One; 2015; 10(3):e0119780. PubMed ID: 25781885
[TBL] [Abstract][Full Text] [Related]
11. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway.
Subramaniam S; Shahani N; Strelau J; Laliberté C; Brandt R; Kaplan D; Unsicker K
J Neurosci; 2005 Mar; 25(11):2838-52. PubMed ID: 15772344
[TBL] [Abstract][Full Text] [Related]
13. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells.
Sahara N; Takeshita A; Ono T; Sugimoto Y; Kobayashi M; Shigeno K; Nakamura S; Shinjo K; Naito K; Shibata K; Otsuki T; Hayashi H; Ohnishi K
Exp Hematol; 2006 Jun; 34(6):736-44. PubMed ID: 16728278
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection of interleukin-6 against NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT signaling pathways.
Fang XX; Jiang XL; Han XH; Peng YP; Qiu YH
Cell Mol Neurobiol; 2013 Mar; 33(2):241-51. PubMed ID: 23161148
[TBL] [Abstract][Full Text] [Related]
15. Insulin Growth Factor 1 Protects Neural Stem Cells Against Apoptosis Induced by Hypoxia Through Akt/Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (Akt/MAPK/ERK) Pathway in Hypoxia-Ishchemic Encephalopathy.
Zhao B; Zheng Z
Med Sci Monit; 2017 Apr; 23():1872-1879. PubMed ID: 28420864
[TBL] [Abstract][Full Text] [Related]
16. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
17. Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells.
Colin D; Limagne E; Jeanningros S; Jacquel A; Lizard G; Athias A; Gambert P; Hichami A; Latruffe N; Solary E; Delmas D
Cancer Prev Res (Phila); 2011 Jul; 4(7):1095-106. PubMed ID: 21467134
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
20. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma.
Nomura T; Huang WC; Seo S; Zhau HE; Mimata H; Chung LW
J Urol; 2007 Jul; 178(1):292-300. PubMed ID: 17499801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
